Northwest & Ethical Investments L.P. Invests $3.53 Million in Kenvue Inc. $KVUE

Northwest & Ethical Investments L.P. bought a new position in shares of Kenvue Inc. (NYSE:KVUE) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 168,626 shares of the company’s stock, valued at approximately $3,529,000.

A number of other institutional investors also recently added to or reduced their stakes in KVUE. Truvestments Capital LLC purchased a new stake in shares of Kenvue in the 1st quarter valued at approximately $37,000. Trust Co. of Vermont lifted its position in shares of Kenvue by 266.8% during the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock worth $33,000 after purchasing an additional 1,150 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd grew its stake in shares of Kenvue by 378.5% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after purchasing an additional 1,287 shares in the last quarter. Ransom Advisory Ltd acquired a new position in shares of Kenvue during the first quarter worth $56,000. Finally, First Pacific Financial purchased a new position in Kenvue in the second quarter valued at $54,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

KVUE stock opened at $17.22 on Thursday. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $32.98 billion, a P/E ratio of 22.95 and a beta of 0.71. The business has a 50 day simple moving average of $16.10 and a 200-day simple moving average of $19.65. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $25.17.

Kenvue (NYSE:KVUE) last announced its earnings results on Monday, November 3rd. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.76 billion for the quarter, compared to analysts’ expectations of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The company’s quarterly revenue was down 3.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th were issued a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.8%. The ex-dividend date of this dividend was Wednesday, November 12th. Kenvue’s dividend payout ratio is presently 110.67%.

Analysts Set New Price Targets

A number of brokerages have issued reports on KVUE. Barclays lifted their price target on Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. The Goldman Sachs Group decreased their target price on Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a research note on Thursday, October 2nd. UBS Group dropped their price target on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 8th. Canaccord Genuity Group restated a “hold” rating and set a $15.00 price objective (down previously from $26.00) on shares of Kenvue in a research report on Wednesday, October 29th. Finally, Rothschild & Co Redburn raised shares of Kenvue from a “neutral” rating to a “buy” rating and dropped their target price for the company from $22.50 to $22.00 in a research report on Friday, September 26th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and an average target price of $20.23.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.